# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $4 price target.
Citigroup analyst Yigal Nochomovitz maintains Macrogenics (NASDAQ:MGNX) with a Buy and lowers the price target from $16 to $14.
BMO Capital analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Market Perform and lowers the price target from ...
Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.59)...
BTIG analyst Kaveri Pohlman downgrades Macrogenics (NASDAQ:MGNX) from Buy to Neutral.
HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $4 price target.
JMP Securities analyst Silvan Tuerkcan maintains Macrogenics (NASDAQ:MGNX) with a Market Outperform and lowers the price tar...
MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 202...